Huadong Medicine Co Ltd - Company Profile
Powered by 
All the data and insights you need on Huadong Medicine Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Huadong Medicine Co Ltd Strategy Report
- Understand Huadong Medicine Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Huadong Medicine Co Ltd (Huadong Medicine) is a producer and supplier of pharmaceutical products. The company’s product range includes capsules to treat nephropathy, respiratory and immune system diseases; and granules. It offers immunosuppressive and gastrointestinal agents, endocrine, digestive system, antineoplastic, cardiovascular, and antibiotic drugs. The company also manufactures cosmetology and medical equipment. It also involves in handling research and development across various areas including diabetes, oncology, autoimmune field, and others. Huadong Medicine is headquartered in Hangzhou, Zhejiang, China.
Headquarters
China
Address
No. 866, Moganshan Road, Hangzhou, Zhejiang, 310011
Website
www.eastchinapharm.com
Telephone
86 571 89903300
No of Employees
14,061
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
000963 (SHE)
Revenue (2021)
$5.6B
9.1%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
8.6%
(2021 vs 2020)
Market Cap*
$7.3B
Net Profit Margin (2022)
XYZ
-0.5%
(2021 vs 2020)
* As of and is in US$
Huadong Medicine Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Immunosuppressive Agents |
| Endocrine Drugs |
| Digestive System Drugs |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company announced a collaboration with Impact Therapeutics for the promotion of Senaparib in China. |
| 2023 | Contracts/Agreements | In October, Huadong Medicine Aesthetics Investment (Hongkong) and ATGC Co entered into a strategic collaboration and licensing agreement under which Sinclair granted a global exclusive license to develop and commercialize ATGC’s botulinum toxin product, ATGC-110 for all aesthetic and therapeutic indications. |
| 2023 | Contracts/Agreements | In August, Hangzhou Zhongmei Huadong Pharmaceutical Co and Arcutis Biotherapeutics entered into a partnership and licensing agreement for the development, manufacture, and commercialization of topical roflumilast in Greater China and Southeast Asia. |
Competitor Comparison
| Key Parameters | Huadong Medicine Co Ltd | Jointown Pharmaceutical Group Co Ltd | Cachet Pharmaceutical Co Ltd | Simcere Pharmaceutical Group Ltd | Shenzhen Salubris Pharmaceuticals Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Hangzhou | Wuhan | Beijing | Nanjing | Shenzhen |
| State/Province | Zhejiang | Hubei | Beijing | Jiangsu | Guangdong |
| No. of Employees | 14,061 | 30,141 | 2,294 | 7,661 | 3,454 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Lu Liang | Chairman; General Manager | Executive Board | 2021 | 49 |
| Zhang Jianfei | Deputy General Manager | Senior Management | 2022 | 48 |
| Zhu Li | Deputy General Manager | Senior Management | 2020 | 48 |
| Wu Hui | Deputy General Manager | Senior Management | 2019 | 54 |
| Chen Bo | Secretary | Senior Management | 2009 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward